{
  "docId": "019de074-a4f4-74e1-8870-171c8951fea8",
  "docSlug": "e0247ed9fbf6e59fd6aeeea6f3eacc2d",
  "documentTitle": "23andMe | Investor Presentation Deck | 57 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 57,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Includes a biological pathway diagram illustrating the interaction between tumor cells and immune cells.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a4f4-74e1-8870-171c8951fea8/41",
  "deckHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8",
  "deckJsonHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8.json",
  "deckAnchorHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.54,
        "y": 0.34
      },
      "kind": "image",
      "text": "CD200:CD200R1 Signaling diagram",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e777483-b2d2-49aa-b33c-68454719091a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.05,
        "y": 0.39
      },
      "kind": "list",
      "text": "CD200R1 is an inhibitory receptor expressed on T-cells and myeloid cells. CD200 is the only known ligand for CD200R1 in humans and is highly expressed in certain cancers. Binding of CD200 to C200R1 decreases the ability of T-cells to recognize and kill cancer cells. Several viruses have co-opted CD200 analogues to suppress and evade the host immune response.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12551049-fcad-483d-9cec-3cc700d10d4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.01,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "References: J Virol 2012;86:6246, J Virol 2004;78:7667, J Immunol 2005;175:4441, Structure 2013;21:820, JCI Insight 2018;3:e96836",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9234be20-b1ed-40f0-8eb4-e9d54344f012",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.528,
        "x": 0.236,
        "y": 0.045
      },
      "kind": "title",
      "text": "CD200R1 is an Immune Checkpoint",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4748f5f-491d-4e68-bd2f-887deb741008",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "2369bf4e-7228-4a63-91fd-3eb236ac77d2",
      "evidence": "CD200R1 is an inhibitory receptor expressed on T-cells and myeloid cells.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 48,
      "from": 36,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "25bf5fec-1759-4ae6-8d05-5ad619b628ea",
      "evidence": "The deck presents 23andMe's research and development pipeline and its immuno-oncology programs",
      "position": 2,
      "objective": "What are the opportunities for 23andMe in therapeutics development?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}